Non-invasive prediction of hepatocellular carcinoma development using serum fibrosis marker in chronic hepatitis C patients

Journal of Gastroenterology

Volumn 49, Issue 11, 2014, Pages 1495-1503

  Tamaki, Nobuharu ^a   Kurosaki, Masayuki ^a   Matsuda, Shuya ^a   Muraoka, Masaru ^a   Yasui, Yutaka ^a   Suzuki, Shoko ^a   Hosokawa, Takanori ^a   Ueda, Ken ^a   Tsuchiya, Kaoru ^a   Nakanishi, Hiroyuki ^a   Itakura, Jun ^a   Takahashi, Yuka ^a   Asahina, Yasuhiro ^b   Izumi, Namiki ^a  

^a MUSASHINO RED CROSS HOSPITAL   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Chronic hepatitis C; FIB 4 index; Hepatocellular carcinoma; Liver fibrosis; Non invasive

Indexed keywords

INTERFERON; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER;

ADULT; ARTICLE; CANCER RISK; CONTROLLED STUDY; FEMALE; FIB 4 INDEX; FOLLOW UP; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCORING SYSTEM; AGED; BIOPSY; BLOOD; CARCINOMA, HEPATOCELLULAR; CHRONIC HEPATITIS C; COMPLICATION; DISEASE COURSE; ENZYMOLOGY; EVALUATION STUDY; KAPLAN MEIER METHOD; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; MIDDLE AGED; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; RISK FACTOR; SEVERITY OF ILLNESS INDEX; THROMBOCYTE COUNT; TIME; VIROLOGY;

ADULT; AGED; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; BIOPSY; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PLATELET COUNT; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 84925357311     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-013-0914-y     Document Type: Article

References (35)

1. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001;345(1):41-52.
2. Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K, Inoue O, et al. The long-term pathological evolution of chronic hepatitis C. Hepatology. 1996;23(6):1334-40.
3. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007;45 (2):507-39.
4. Dienstag JL. The role of liver biopsy in chronic hepatitis C. Hepatology. 2002;36(5 Suppl 1):S152-60.
5. Namiki I, Nishiguchi S, Hino K, Suzuki F, Kumada H, Itoh Y, et al. Management of hepatitis C; Report of the Consensus Meeting at the 45th Annual Meeting of the Japan Society of Hepatology (2009). Hepatol Res. 2010;40(4):347-68.
6. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology. 1994;20(1 Pt 1):15-20.
7. Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol. 2002;97(10):2614-8.
8. Castera L, Negre I, Samii K, Buffet C. Pain experienced during percutaneous liver biopsy. Hepatology. 1999;30(6):1529-30.
9. Ziol M, Handra-Luca A, Kettaneh A, Christidis C, Mal F, Kazemi F, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology. 2005;41(1):48-54.
10. Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005;128(2):343-50.
11. Friedrich-Rust M, Nierhoff J, Lupsor M, Sporea I, Fierbinteanu-Braticevici C, Strobel D, et al. Performance of acoustic radiation force impulse imaging for the staging of liver fibrosis: a pooled meta-analysis. J Viral Hepat. 2012;19(2):e212-9.
12. Tamaki N, Kurosaki M, Matsuda S, Nakata T, Muraoka M, Suzuki Y, et al. Prospective comparison of real-time tissue elastography and serum fibrosis markers for the estimation of liver fibrosis in chronic hepatitis C patients. Hepatol Res. 2013;6(10): 12179.
13. Williams AL, Hoofnagle JH. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis. Gastroenterology. 1988;95(3):734-9.
14. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38(2):518-26.
15. Forns X, Ampurdanes S, Llovet JM, Aponte J, Quinto L, Martinez-Bauer E, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology. 2002;36(4 Pt 1):986-92.
16. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet. 2001;357 (9262):1069-75.
17. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317-25.
18. Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology. 2007;46(1):32-6.
19. Holmberg SD, Lu M, Rupp LB, Lamerato LE, Moorman AC, Vijayadeva V, et al. Noninvasive serum fibrosis markers for screening and staging chronic hepatitis C virus patients in a large US cohort. Clin Infect Dis. 2013;57(2):240-6.
20. Tamaki N, Kurosaki M, Tanaka K, Suzuki Y, Hoshioka Y, Kato T, et al. Noninvasive estimation of fibrosis progression overtime using the FIB-4 index in chronic hepatitis C. J Viral Hepat. 2013;20(1):72-6.
21. Asahina Y, Tsuchiya K, Tamaki N, Hirayama I, Tanaka T, Sato M, et al. Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. Hepatology. 2010;52(2): 518-27.
22. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996;24(2):289-93.
23. Masuzaki R, Tateishi R, Yoshida H, Goto E, Sato T, Ohki T, et al. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatology. 2009;49(6):1954-61.
24. Vergniol J, Foucher J, Terrebonne E, Bernard PH, le Bail B, Merrouche W, et al. Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C. Gastroenterology. 2011;140(7):1970-9, 1979.e1-3.
25. Nunes D, Fleming C, Offner G, Craven D, Fix O, Heeren T, et al. Noninvasive markers of liver fibrosis are highly predictive of liver-related death in a cohort of HCV-infected individuals with and without HIV infection. Am J Gastroenterol. 2010;105(6): 1346-53.
26. Yu ML, Lin SM, Lee CM, Dai CY, Chang WY, Chen SC, et al. A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy. Hepatology. 2006;44(5):1086-97.
27. Kurosaki M, Matsunaga K, Hirayama I, Tanaka T, Sato M, Komatsu N, et al. The presence of steatosis and elevation of alanine aminotransferase levels are associated with fibrosis progression in chronic hepatitis C with non-response to interferon therapy. J Hepatol. 2008;48(5):736-42.
28. Kumada T, Toyoda H, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, et al. Incidence of hepatocellular carcinoma in hepatitis C carriers with normal alanine aminotransferase levels. J Hepatol. 2009;50(4):729-35.
29. Izumi N, Asahina Y, Kurosaki M, Yamada G, Kawai T, Kajiwara E, et al. Inhibition of hepatocellular carcinoma by PegIFNalpha-2a in patients with chronic hepatitis C: a nationwide multicenter cooperative study. J Gastroenterol. 2012;9:9.
30. Nagamine T, Ohtuka T, Takehara K, Arai T, Takagi H, Mori M. Thrombocytopenia associated with hepatitis C viral infection. J Hepatol. 1996;24(2):135-40.
31. Park LS, Tate JP, Justice AC, Lo Re V 3rd, Lim JK, Brau N, et al. FIB-4 index is associated with hepatocellular carcinoma risk in HIV-infected patients. Cancer Epidemiol Biomarkers Prev. 2011;20(12):2512-7.
32. Zarski JP, Sturm N, Guechot J, Paris A, Zafrani ES, Asselah T, et al. Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study. J Hepatol. 2012;56(1):55-62.
33. Poynard T, Ngo Y, Perazzo H, Munteanu M, Lebray P, Moussalli J, et al. Prognostic value of liver fibrosis biomarkers: a metaanalysis. Gastroenterol Hepatol (N Y). 2011;7(7):445-54.
34. Castera L, Foucher J, Bernard PH, Carvalho F, Allaix D, Merrouche W, et al. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology. 2010;51 (3):828-35.
35. Fraquelli M, Rigamonti C, Casazza G, Conte D, Donato MF, Ronchi G, et al. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut. 2007;56(7):968-73.